Genfit’s Iqirvo Wins EU Approval for Liver Condition
Company Announcements

Genfit’s Iqirvo Wins EU Approval for Liver Condition

Genfit SA (GNFT) has released an update.

Genfit SA has announced the European Commission’s approval of Iqirvo (Elafibranor), a new treatment option for Primary Biliary Cholangitis. The approval follows the drug’s positive reception by the EMA and the U.S. FDA earlier this year. This milestone paves the way for a €26.5 million payment to Genfit, bolstering their efforts to develop treatments for severe liver diseases.

For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskGenfit’s Revenue Surge Driven by Key Milestone
TipRanks Auto-Generated NewsdeskGENFIT SA Showcases Robust 2024 Financial Health
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App